Scholarlink

<p>Early diagnosis of prostate cancer (PCa) is crucial, but the widely used prostate-specific antigen (PSA) biomarker lacks specificity in the 4.0–10.0&#xa0;ng/mL grey zone, causing many unnecessary biopsies. This study assessed urinary DLX1/HOXC6 mRNA’s diagnostic performance for PCa (both low-grade and high-grade) in Chinese men with grey-zone PSA. 584 participants with PSA 4.0–10.0&#xa0;ng/mL were prospectively enrolled in two cohorts (Cohort A: n = 258; Cohort B: n = 326). Urine samples were analyzed via RT-PCR to detect DLX1/HOXC6 expression levels. A DH-Score model was developed by logistic regression and its diagnostic performance was validated. The RT-PCR assay demonstrated excellent precision, linearity, and stability against common interferents. In Cohort A, the DH-Score achieved an area under the receiver operating characteristic curve (AUC) of 0.951 (95% CI 0.917–0.974), with a sensitivity of 85.6% and a specificity of 89.1%. Validation in Cohort B showed consistent performance (AUC = 0.933, sensitivity = 84.3%, specificity = 88.7%), demonstrating robust accuracy. A negative predictive value of 85–89% could reduce unnecessary biopsies by excluding benign cases in the gray zone of the PSA. In Conclusion, DH-Score offers a non-invasive, accurate PCa risk stratification in the PSA grey zone, reducing unnecessary biopsies while preserving high diagnostic efficacy in Chinese men.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Identification of prostate cancer by urinary DLX1/HOXC6 expression in Chinese population with prostate-specific antigen levels of 4–10 ng/mL

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月29日

查看全文
  • Dongxu Zhang,
  • Jianglei Xu,
  • Junhong Wang,
  • Junhui Jiang

摘要

Early diagnosis of prostate cancer (PCa) is crucial, but the widely used prostate-specific antigen (PSA) biomarker lacks specificity in the 4.0–10.0 ng/mL grey zone, causing many unnecessary biopsies. This study assessed urinary DLX1/HOXC6 mRNA’s diagnostic performance for PCa (both low-grade and high-grade) in Chinese men with grey-zone PSA. 584 participants with PSA 4.0–10.0 ng/mL were prospectively enrolled in two cohorts (Cohort A: n = 258; Cohort B: n = 326). Urine samples were analyzed via RT-PCR to detect DLX1/HOXC6 expression levels. A DH-Score model was developed by logistic regression and its diagnostic performance was validated. The RT-PCR assay demonstrated excellent precision, linearity, and stability against common interferents. In Cohort A, the DH-Score achieved an area under the receiver operating characteristic curve (AUC) of 0.951 (95% CI 0.917–0.974), with a sensitivity of 85.6% and a specificity of 89.1%. Validation in Cohort B showed consistent performance (AUC = 0.933, sensitivity = 84.3%, specificity = 88.7%), demonstrating robust accuracy. A negative predictive value of 85–89% could reduce unnecessary biopsies by excluding benign cases in the gray zone of the PSA. In Conclusion, DH-Score offers a non-invasive, accurate PCa risk stratification in the PSA grey zone, reducing unnecessary biopsies while preserving high diagnostic efficacy in Chinese men.